The coronavirus main protease, which plays a pivotal role in viral gene expression and replication through the proteolytic processing of replicase polyproteins, is an attractive target for anti-CoV drug design. The inhibition of viral proteases necessary for proteolytic processing of polyproteins has been a successful strategy in the treatment of human immunodeficiency virus (HIV) and hepatitis C respectively, proving the potential of protease inhibitors for the treatment of viral infections. Similarly, the main protease of SARS-CoV-2 is thought to be essential for viral replication and is therefore regarded as a promising target for antiviral therapy of Covid-19.

Suitable for developing methods to screen potential inhibitors of coronavirus proteases

Compatible with high-throughput handling systems.

Covidyte IF670 is a peptide substrate containing a 12-amino acid sequence (VNSTLQSGLRKM) that can be cleaved by coronavirus proteases. The dark-FRET peptide contains Tide Quencher^™ 5 (TQ5) as a quencher and iFluor 670 as a fluorescent donor on the N- and C- terminals respectively where the fluorescence of iFluor 670 is effectively quenched by TQ5 when the peptide is intact. When the peptide is hydrolyzed by coronavirus proteases, the iFluor 670 fragment generates significantly enhanced fluorescence since its fluorescence is no longer quenched by TQ5. The activity of coronavirus proteases can be effectively monitored by the fluorescence intensity of iFluor 670.

For additional information on our range of Biochemicals, please complete this form.

Covidyte is a trademark of AAT Bioquest, Inc.

Tide Quencher is a trademark of AAT Bioquest, Inc.